The promise of an objective, consistent score for a skin condition like psoriasis is a powerful one. In clinical practice, the Psoriasis Area and Severity Index (PASI) is a gold standard, but its application is notoriously subjective. MyMonitor.Ai, a 2024-founded startup from Philadelphia, is betting that an AI can do it better, and crucially, that it can do it fairly for all skin tones. The company’s platform, which it describes as a melanin-aware imaging system, is designed to generate quantitative severity scores from a single uploaded image, a capability backed by peer-reviewed research [PubMed, retrieved 2026].
The Clinical and Research Wedge
MyMonitor.Ai is pursuing a dual-market strategy. For practicing dermatologists, the platform offers a tool for real-time flare tracking and disease progression monitoring [MyMonitor.ai, retrieved 2024]. The more ambitious application lies in clinical research. Here, the company positions its system as a monitoring platform for trials, incorporating tokenization and zero-knowledge proof systems to address the intense data privacy and integrity requirements of pharmaceutical sponsors and contract research organizations (CROs) [Serchen, retrieved 2024].
Why Melanin-Aware Imaging Is the Core
What separates MyMonitor.Ai from a generic computer vision project is its explicit focus on skin of color. The company states its mission is to improve care “especially for people with skin-of-color, who are often misdiagnosed or underserved” [15 Percent Pledge, retrieved 2025]. Most dermatological AI training datasets have historically been skewed toward lighter skin tones, leading to models that perform poorly on darker skin. By building melanin-aware imaging into its core, MyMonitor.Ai is attempting to solve for a well-documented bias at the model level.
The Early-Stage Landscape
As a pre-seed company that participated in the C10 Labs accelerator [LinkedIn, Nov 2024], MyMonitor.Ai is navigating a space with established players. The competitive set includes companies like Legit.Health and tools like Thea Care’s SkinGen Melanin.
- Technical validation. The publication of research on a “Single-Shot PASI” system in a peer-reviewed journal provides a critical foundation of scientific credibility [PubMed, retrieved 2026].
- Regulatory pathway. The company has not publicly detailed a FDA submission strategy for its diagnostic claims.
- Commercial focus. Pursuing both the clinician and the clinical trial sponsor simultaneously requires distinct sales motions and evidence generation.
The standard of care today for a patient with moderate-to-severe psoriasis involves regular clinic visits where a dermatologist visually inspects the skin. The process is subjective, and the documentation is often qualitative. In clinical trials, this subjectivity is a major source of noise. MyMonitor.Ai’s bet is that a more objective, consistent, and inclusive scoring tool can improve outcomes in both settings, turning the clinician’s eye into a calibrated instrument.
Sources
- [MyMonitor.ai, retrieved 2024] MyMonitor.ai homepage | https://mymonitor.ai/
- [Serchen, retrieved 2024] MyMonitor.Ai Product Details | https://www.serchen.co.uk/company/mymonitor-ai
- [15 Percent Pledge, retrieved 2025] MyMonitor,Ai business profile | https://15percentpledge.org/business/mymonitor-ai-tok5obrh7kdnputzu0ljg
- [PubMed, retrieved 2026] Artificial intelligence for the automated single-shot assessment of psoriasis severity | https://pubmed.ncbi.nlm.nih.gov/35739649/
- [LinkedIn, Nov 2024] C10 Labs Winter Cohort announcement | https://www.linkedin.com/posts/matthewhcrane_episode-33-of-the-coworking-chronicles-has-activity-7427720782568665088-JJLo